Literature DB >> 1902247

Immune cell activation in melioidosis: increased serum levels of interferon-gamma and soluble interleukin-2 receptors without change in soluble CD8 protein.

A E Brown1, D A Dance, Y Suputtamongkol, W Chaowagul, S Kongchareon, H K Webster, N J White.   

Abstract

To evaluate immune cell activation in patients with melioidosis, serum samples were assayed for interferon-gamma (IFN-gamma), soluble interleukin-2 receptors (sIL-2R), and soluble CD8 protein (sCD8). Forty patients with sepsis (23 fatal cases, 17 survivors) and 13 with localized disease were studied during acute illness; 12 additional patients were studied after discharge while on maintenance antimicrobial therapy. Serum concentrations of IFN-gamma and sIL-2R were greatly elevated, but sCD8 concentrations were not. These levels increased with disease severity and were associated with fatal outcomes. Macrophage activation by high concentrations of the cytokine IFN-gamma may contribute to pathophysiology and death in septicemic patients. Both IFN-gamma and sIL-2R seem to be predictive of outcome in patients with severe melioidosis and may prove useful in detection of relapse.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1902247     DOI: 10.1093/infdis/163.5.1145

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

Review 1.  Human Melioidosis.

Authors:  I Gassiep; M Armstrong; R Norton
Journal:  Clin Microbiol Rev       Date:  2020-03-11       Impact factor: 26.132

Review 2.  Melioidosis: epidemiology, pathophysiology, and management.

Authors:  Allen C Cheng; Bart J Currie
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

3.  The CXC chemokines gamma interferon (IFN-gamma)-inducible protein 10 and monokine induced by IFN-gamma are released during severe melioidosis.

Authors:  F N Lauw; A J Simpson; J M Prins; S J van Deventer; W Chaowagul; N J White; T van der Poll
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

4.  Cytokine gene expression in innately susceptible BALB/c mice and relatively resistant C57BL/6 mice during infection with virulent Burkholderia pseudomallei.

Authors:  G C Ulett; N Ketheesan; R G Hirst
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

5.  Immunostimulatory CpG oligodeoxynucleotide confers protection in a murine model of infection with Burkholderia pseudomallei.

Authors:  Surasakdi Wongratanacheewin; Wannapa Kespichayawattana; Pakamas Intachote; Sathit Pichyangkul; Rasana W Sermswan; Arthur M Krieg; Stitaya Sirisinha
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

6.  Burkholderia pseudomallei Capsule Exacerbates Respiratory Melioidosis but Does Not Afford Protection against Antimicrobial Signaling or Bacterial Killing in Human Olfactory Ensheathing Cells.

Authors:  Samantha J Dando; Deepak S Ipe; Michael Batzloff; Matthew J Sullivan; David K Crossman; Michael Crowley; Emily Strong; Stephanie Kyan; Sophie Y Leclercq; Jenny A K Ekberg; James St John; Ifor R Beacham; Glen C Ulett
Journal:  Infect Immun       Date:  2016-06-23       Impact factor: 3.441

7.  Analogous cytokine responses to Burkholderia pseudomallei strains contrasting in virulence correlate with partial cross-protection in immunized mice.

Authors:  Glen C Ulett; Natkunam Ketheesan; Timothy W Clair; Catriona L McElnea; Jodie L Barnes; Robert G Hirst
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

8.  Obligatory role of gamma interferon for host survival in a murine model of infection with Burkholderia pseudomallei.

Authors:  P Santanirand; V S Harley; D A Dance; B S Drasar; G J Bancroft
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

9.  Evaluation of surrogate animal models of melioidosis.

Authors:  Jonathan Mark Warawa
Journal:  Front Microbiol       Date:  2010-12-29       Impact factor: 5.640

10.  Development of vaccines against burkholderia pseudomallei.

Authors:  Natasha Patel; Laura Conejero; Melanie De Reynal; Anna Easton; Gregory J Bancroft; Richard W Titball
Journal:  Front Microbiol       Date:  2011-09-27       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.